Adriamycin in combination for the treatment of breast cancer.A southwest oncology group study
Year: 1978
Type: article
Abstract: Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1, plus 5-FU day 1 and 8, and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8, cyclophosphamide day 1 and methotrexate day 1 (AFCM). These courses were repeated every 21 days. The response rate was 44/105 (42%) AF, 44/103 (43%) AFC and 52/105 (49%) AFCM. The length of response was 22, 33 and 35 weeks, respectively, for AF, AFC and AFCM (P = 0.21). The median survival, 64 weeks, was equal in all three limbs. The major toxicity was leukopenia. Twenty-eight percent developed a WBC of less than 2,000/microliter, which resulted in seven deaths (2.2%).
Source: Cancer
Authors: B. Tranum, B. Hoogstraten, A. Kennedy, C. B. Vaughn, B. Samal, T. Thigpen, S. Rivkin, F. Smith, R. L. Palmer, J. Costanzi, W. G. Tucker, H. Wilson, T. R. Maloney
Institutions: American Cancer Society, University of Arkansas for Medical Sciences, University of Kansas Medical Center, SWOG Cancer Research Network, Wayne State University, University of Mississippi Medical Center, Swedish Medical Center, Baylor College of Medicine, Baylor Scott & White Medical Center - Temple, The University of Texas Medical Branch at Galveston, Borgess Medical Center, The Ohio State University, Wilford Hall Ambulatory Surgical Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W1985997571